52 research outputs found

    The Grizzly, October 26, 2017

    Get PDF
    History of Halloween • Senior English Majors go Gothic • SAO Plans Halloween Trip to Dorney • Senior Halloween Party: An Ursinus Tradition • Fright Night: Phoenixville Theatre Hosts Horror Film Series • Spooky Ursinus Folk • Something Wicked This Way Comes • Opinions: A Ghost Story Haunts with Quiet Pain and Loss; Trick-or-Treating Should End for Children Older than Thirteen • Superstitions Win Confidence for Ursinus Student Athletes • First Year Athletes Face Scary New Adjustmentshttps://digitalcommons.ursinus.edu/grizzlynews/1629/thumbnail.jp

    The Grizzly, November 9, 2017

    Get PDF
    Department of Education Rolls Back Piece of Title IX • Joe DeSimone \u2786 Receives Heinz Award • New Education Major Created • Nadler Awarded Tow Fellowship • Dr. Kerr Appears on Full Frontal with Samantha Bee • History of a Historian • Opinions: Male Gun Violence Must End with Restrictive Gun Legislation; JFK\u27s Legacy Should be More Than Assassination Conspiracies • Senior Athletes Share Memories as Fall Sports Seasons Wind to a Close • Football Drops Three of Last Four Gameshttps://digitalcommons.ursinus.edu/grizzlynews/1631/thumbnail.jp

    The Grizzly, November 16, 2017

    Get PDF
    Democrats Sweep Local Elections • Sustainability Office Recognized by the Princeton Review • Bear2Bear Fund Aids Students with Emergency Expenses • UCDC Fall Show, Once Removed, Opens This Thursday • Pride Shines at Ursinus • Build Character, Write Now • Opinions: Student Leaders Must be Better Allies Through Their Actions; Paradise Papers Reveal Unethical Tax Avoidance by Tech Companies • UCXC Finishes Strong • Men\u27s Basketball Picked Fourth in Preseason Pollhttps://digitalcommons.ursinus.edu/grizzlynews/1632/thumbnail.jp

    Missense mutations in the copper transporter gene ATP7A cause X-Linked distal hereditary motor neuropathy

    Get PDF
    Distal hereditary motor neuropathies comprise a clinically and genetically heterogeneous group of disorders. We recently mapped an X-linked form of this condition to chromosome Xq13.1-q21 in two large unrelated families. The region of genetic linkage included ATP7A, which encodes a copper-transporting P-type ATPase mutated in patients with Menkes disease, a severe infantile-onset neurodegenerative condition. We identified two unique ATP7A missense mutations (p.P1386S and p.T994I) in males with distal motor neuropathy in two families. These molecular alterations impact highly conserved amino acids in the carboxyl half of ATP7A and do not directly involve the copper transporter's known critical functional domains. Studies of p.P1386S revealed normal ATP7A mRNA and protein levels, a defect in ATP7A trafficking, and partial rescue of a S. cerevisiae copper transport knockout. Although ATP7A mutations are typically associated with severe Menkes disease or its milder allelic variant, occipital horn syndrome, we demonstrate here that certain missense mutations at this locus can cause a syndrome restricted to progressive distal motor neuropathy without overt signs of systemic copper deficiency. This previously unrecognized genotype-phenotype correlation suggests an important role of the ATP7A copper transporter in motor-neuron maintenance and function

    Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

    Get PDF
    IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570
    • …
    corecore